Document G6Vq76JwrxKEKYMRabMO7VgyY

53. Smith, M. T., Zhang, L., Rothman, N., Wang, Y., Hayes, R B., Li, 0. L., and Yin, S. N. Interphase cytogenetics of workers exposed to benzene. Environ.Health Perspect., 105: 1325-1329,1996. 54. Crane, M. M., Keating, M. J., Trujillo, J. M., Labarthe, D. R, and Frankowski, R F. Environmental exposures in cytogenetically defmed subsets of acute nonlymphocytic leukemia. JAMA, 262: 634-639, 1989. 55. Van den Berghe, H., Louwagie, A, Broeckaert-Van Orshoven, A, David, G., and Verwilghen, R Chromosome analysis in two unusual malignant blood disorders presumably induced by benzene. Blood, 53: 558-566, 1979. 56. Le Beau, M. M. and Rowley, J. D. Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance. Adv.Hum.Genet., 15: 1-54,1986. 57. Stillman, W. S., Varella-Garcia, M., and Irons, R D. The benzene metabolite, hydroquinone, selectively induces 5q31-and-7 in human CD34+CDI9- bone marrow cells. Exp.Hematol., 28: 169-176,2000. 58. Pedersen-Bjergaard, J. and Rowley, J. D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood, 83: 2780-2786, 1994. 59. Gill-Super, H., McCabe, N., and Thirman, M. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood, 83: 2780-2786, 1993. 60. Stone, R, Neuberg, D., Soiffer, R, Whelan, M., Leavitt, P., Aster, J., Takvorian, R, Rabinowe, S., Ritz, J., Freedman, A, and Nadler, L. Myelodysplastic syndrome (MDS) as a complication after autologous bone marrow transplantation (ABMT) for nonhodgkin's lymphoma (NHL). Blood 82, 196a. 93. 61. Murphy, S. B. Secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J.Clin.Oncol., 11 : 199-201, 1993. 62. Sandoval, c., Pui, C.-H., Bowman, L. c., Heaton, D., Hurwitz, C. A, Raimondi, S. c., Behm, F. G., and Head, D. R Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J.Clin.Oncol., 11: 1039-1045,1993. 63. Chen, H. W. and Eastmond, D. A Topoisomerase inhibition by phenolic metabolites: A potential mechanism for benzene's clastogenic effects. Carcinogenesis, 16: 2301-2307, 1995. 64. Chen, H. W., Frantz, c., and Eastmond, D. A Inhibition of topoisomerase enzymes by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. Benzene '95: Program for the International Conference on the Toxicity, Carcinogenesis, and Epidemiology of Benzene July 17-20. 95. 35 SH ELL-MCCLU RG-059753